Antiphospholipid antibodies as biomarkers in psychiatry: review of psychiatric manifestations in antiphospholipid syndrome

Abstract

Antiphospholipid syndrome (APS) has been implicated in a range of neuropsychiatric presentations. However, there is a paucity of systematic studies on APS in psychiatry. This paper reports the clinical manifestations of APS that are relevant to psychiatrists. The aspects of APS pathogenesis, diagnosis, and treatment presented in this paper are based on a literature review. Treatment-resistant and atypical psychiatric illnesses, severe cognitive dysfunction, migraines, transient ischaemic attacks, and thromboembolic episodes, along with characteristic skin manifestations are the common clinical features of this syndrome. Antiphospholipid antibodies (aPL) may have a causal role in the development of some neuropsychiatric conditions. The existing criteria of APS may not apply to psychiatric patients, which may result in the underdiagnosis of APS in psychiatry. There is no evidence-based guidance available for the treatment of APS in patients with psychiatric symptoms. The treatment of APS with antithrombotic agents in case reports has been reported to yield dramatic improvements in complex and treatment-resistant cases. The possibility of a causal role of aPL in high-morbidity conditions, such as psychosis, depression, and dementia, requires the psychiatrist to be vigilant to the occurrence of this syndrome. There is an urgent need to conduct studies that elucidate the role of aPL in psychiatric presentations, identify patient characteristics, and consider whether new criteria with greater applicability in psychiatry are needed.

Cytokine secretion and the risk of depression development in patients with connective tissue diseases

“…It has also been suggested that aPL antibodies may bind to neural tissue, deregulating their functions, and resulting in a direct pathogenic effect . The role of aPL in other neuropsychological conditions, such as psychosis and dementia, has also been implicated …”

“…Chronic pain can independently contribute to the pathogenesis of depression, through elevation of inflammatory cytokines IL‐1β, IL‐6, and TNF‐α . Here, we review the prevalence and characteristics of depression, and its correlation to the levels of inflammatory cytokines and disease activity among different CTD (Tables and ).…”

Neuroprotective effects of trigonelline in kainic acid-induced epilepsy: Behavioral, biochemical, and functional insights

“…A considerable rise in MDA has been associated with oxidative degradation in cellular proteins ( Miao et al, 2021 ), which we also found. Furthermore, antioxidant components such as GSH were depleted in the KA-induced model in our investigation, which was consistent with previous results ( Rege and Mackworth-Young, 2015 ). Trigonelline has been shown to reduce oxidative stress as well as boost the antioxidant defense system in the KA group in this research.…”

Management of Psychosis in Neuropsychiatric Lupus

“…Passive immunization with monoclonal human anticardiolipin antibodies led to NP events in mice [38]. Apart from triggering vascular thrombosis, the antiphospholipid antibodies interact with the neurotransmitter receptors, perturb the inflammatory cytokines in the CNS and alter the synaptoneurosomes [39].…”